Evaluating Bone Health and Vitamin D Supplementation to Improve Pregnancy Outcomes in Women with Epilepsy

What this Trial Is About

This research aims to study women with epilepsy WWE who are of childbearing age, focusing on how managing bone health can improve pregnancy outcomes. The study seeks to establish evidence-based vitamin D supplementation strategies for these women, addressing the challenges of epilepsy management during pregnancy. Epilepsy affects a significant number of women in this age group, making optimal bone metabolism care an important part of their obstetric treatment. Participants in the study are divided into two groups one group receives daily supplementation of calcium and vitamin D according to their early pregnancy vitamin D levels, while the other group receives standard care without intervention. Vitamin D levels are assessed between 10 and 14 weeks of pregnancy. Supplement doses vary depending on vitamin D status, ranging from 500 IU to 1300 IU daily, combined with a consistent 725 mg of calcium. Throughout the pregnancy, researchers monitor bone metabolism indicators in both the mothers and their offspring at various times, including early pregnancy, delivery, and postnatal periods. Secondary outcomes include live birth rates without major congenital malformations and maternal bone health markers during pregnancy. The study involves regular testing and follow-up to assess the impact of the supplementation on bone health and pregnancy outcomes, with the trial lasting until January 2035.

Bone Management in Pregnancy Outcomes in Epilepsy